The immunology of renal cell carcinoma

CM Díaz-Montero, BI Rini, JH Finke - Nature Reviews Nephrology, 2020‏ - nature.com
Renal cell carcinoma (RCC) is the most common type of kidney cancer and comprises
several subtypes with unique characteristics. The most common subtype (~ 70% of cases) is …

Resistance to systemic therapies in clear cell renal cell carcinoma: mechanisms and management strategies

P Makhov, S Joshi, P Ghatalia, A Kutikov… - Molecular cancer …, 2018‏ - aacrjournals.org
Renal cell carcinoma (RCC) is the most common form of kidney cancer. It is categorized into
various subtypes, with clear cell RCC (ccRCC) representing about 85% of all RCC tumors …

[HTML][HTML] Exosomes in the diagnosis and treatment of renal cell cancer

S Boussios, P Devo, ICA Goodall, K Sirlantzis… - International Journal of …, 2023‏ - mdpi.com
Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer originating from
renal tubular epithelial cells, with clear cell RCC comprising approximately 80% of cases …

N6-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell …

Y Chen, Z Lu, C Qi, C Yu, Y Li, W Huan, R Wang… - Molecular cancer, 2022‏ - Springer
Background Sunitinib resistance can be classified into primary and secondary resistance.
While accumulating research has indicated several underlying factors contributing to …

TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1

C Zhang, Y Duan, M **a, Y Dong, Y Chen… - Clinical Cancer …, 2019‏ - aacrjournals.org
Purpose: Despite the FDA approval of mTOR inhibitors (mTORi) for the treatment of renal
cell carcinoma (RCC), the benefits are relatively modest and the few responders usually …